These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

293 related items for PubMed ID: 33939497

  • 1. Erenumab prevents the occurrence of migraine attacks and not just migraine days: Post-hoc analyses of a phase III study.
    Diener HC, Ashina M, Ritter S, Paiva Da Silva Lima G, Rasmussen S, Zielman R, Tfelt-Hansen P.
    Cephalalgia; 2021 Oct; 41(11-12):1262-1267. PubMed ID: 33939497
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A Randomized Phase 2 Study of Erenumab for the Prevention of Episodic Migraine in Japanese Adults.
    Sakai F, Takeshima T, Tatsuoka Y, Hirata K, Lenz R, Wang Y, Cheng S, Hirama T, Mikol DD.
    Headache; 2019 Nov; 59(10):1731-1742. PubMed ID: 31612482
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Post hoc analysis of clinical trial data and pharmacokinetic data to assess wearing-off of erenumab within monthly treatment cycle.
    Dodick DW, Blumenfeld AM, Halker Singh RB, Williams R, Zhang F, Chen PW, Hsu CP, Peng C, Snellman J, Chehrenama M, Ailani J.
    Headache; 2023 Feb; 63(2):233-242. PubMed ID: 36226464
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. ARISE: A Phase 3 randomized trial of erenumab for episodic migraine.
    Dodick DW, Ashina M, Brandes JL, Kudrow D, Lanteri-Minet M, Osipova V, Palmer K, Picard H, Mikol DD, Lenz RA.
    Cephalalgia; 2018 May; 38(6):1026-1037. PubMed ID: 29471679
    [Abstract] [Full Text] [Related]

  • 14. Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a post-hoc analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension.
    Lipton RB, Tepper SJ, Silberstein SD, Kudrow D, Ashina M, Reuter U, Dodick DW, Zhang F, Rippon GA, Cheng S, Mikol DD.
    Cephalalgia; 2021 Jan; 41(1):6-16. PubMed ID: 33269951
    [Abstract] [Full Text] [Related]

  • 15. Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study.
    Barbanti P, Aurilia C, Cevoli S, Egeo G, Fofi L, Messina R, Salerno A, Torelli P, Albanese M, Carnevale A, Bono F, D'Amico D, Filippi M, Altamura C, Vernieri F, EARLY Study Group.
    Headache; 2021 Oct; 61(9):1351-1363. PubMed ID: 34309862
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study.
    Goadsby PJ, Paemeleire K, Broessner G, Brandes J, Klatt J, Zhang F, Picard H, Lenz R, Mikol DD.
    Cephalalgia; 2019 Jun; 39(7):817-826. PubMed ID: 30982348
    [Abstract] [Full Text] [Related]

  • 17. Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study.
    Takeshima T, Sakai F, Hirata K, Imai N, Matsumori Y, Yoshida R, Peng C, Cheng S, Mikol DD.
    Headache; 2021 Jun; 61(6):927-935. PubMed ID: 34153117
    [Abstract] [Full Text] [Related]

  • 18. Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study.
    Tepper SJ, Ashina M, Reuter U, Brandes JL, Doležil D, Silberstein SD, Winner P, Zhang F, Cheng S, Mikol DD.
    Cephalalgia; 2020 May; 40(6):543-553. PubMed ID: 32216456
    [Abstract] [Full Text] [Related]

  • 19. Timing and durability of response to erenumab in patients with episodic migraine.
    McAllister PJ, Turner I, Reuter U, Wang A, Scanlon J, Klatt J, Chou DE, Paiva da Silva Lima G.
    Headache; 2021 Nov; 61(10):1553-1561. PubMed ID: 34841526
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.